|1.||Linz, W: 2 articles (03/2003 - 04/2000)|
|2.||Langer, K H: 1 article (03/2003)|
|3.||Hropot, M: 1 article (03/2003)|
|4.||Wiemer, Gabriele: 1 article (03/2003)|
|5.||Grötsch, H: 1 article (03/2003)|
|6.||Jänichen, G: 1 article (01/2001)|
|7.||Unger, T: 1 article (01/2001)|
|8.||Xia, Q G: 1 article (01/2001)|
|9.||Spitznagel, H: 1 article (01/2001)|
|10.||Gohlke, P: 1 article (01/2001)|
|1.||Cardiomegaly (Heart Hypertrophy)
01/01/2001 - "Fonsartan (HR720) treatment attenuated cardiac hypertrophy when treatment started 30 min or later after MI, limited infarct size when treatment initiated 3 and 24 h after MI, decreased left ventricular end-diastolic pressure when treatment started 3 h to 7 days after MI, and improved dP/dt(max) when treatment commenced 24 h and 7 days after MI compared to untreated infarct group. "
01/01/1997 - "We evaluated the renal effects of the new angiotensin II type 1 (AT ) receptor antagonist, HR 720, in the stroke-prone spontaneously hypertensive rat. "
04/01/2000 - "In this study, we investigated the outcome of lifelong treatment with the angiotensin II type 1 receptor (AT(1)) blocker fonsartan (HR 720) in young stroke-prone spontaneously hypertensive rats (SHR-SP). "
01/01/2001 - "Therefore, the purpose of the present study was to compare the effects of very early (30 min after MI), early (3 and 24 h after MI) and delayed (7 days after MI) treatments with the angiotensin AT(1) receptor antagonist fonsartan (HR 720) on cardiac morphological and hemodynamic parameters in a rat model of MI-induced heart failure and to establish the therapeutic window for the start of treatment. "
|5.||Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
|2.||Type 1 Angiotensin Receptor
|5.||NG-Nitroarginine Methyl Ester (L-NAME)